Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer

PURPOSE: To review the toxicity and clinical outcomes for patients who underwent repeat chest wall or breast irradiation (RT) after local recurrence. METHODS AND MATERIALS: Between 1993 and 2005, 81 patients underwent repeat RT of the breast or chest wall for locally recurrent breast cancer at eight institutions. The median dose of the first course of RT was 60 Gy and was 48 Gy for the second course. The median total radiation dose was 106 Gy (range, 74.4-137.5 Gy). At the second RT course, 20% received twice-daily RT, 54% were treated with concurrent hyperthermia, and 54% received concurrent chemotherapy. RESULTS: The median follow-up from the second RT course was 12 months (range, 1-144 months). Four patients developed late Grade 3 or 4 toxicity. However, 25 patients had follow-up >20 months, and no late Grade 3 or 4 toxicities were noted. No treatment-related deaths occurred. The development of Grade 3 or 4 late toxicity was not associated with any repeat RT variables. The overall complete response rate was 57%. No repeat RT parameters were associated with an improved complete response rate, although a trend was noted for an improved complete response with the addition of hyperthermia that was close to reaching statistical significance (67% vs. 39%, p = 0.08). The 1-year local disease-free survival rate for patients with gross disease was 53% compared with 100% for those without gross disease (p < 0.0001). CONCLUSIONS: The results of our study have shown that repeat RT of the chest wall for patients with locally recurrent breast cancer is feasible, because it is associated with acceptable acute and late morbidity and encouraging local response rates.     

The Clinical Utility of DCISionRT® on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery

Background

The role of radiation therapy (RT) following breast-conserving surgery (BCS) in ductal carcinoma in situ (DCIS) remains controversial. Trials have not identified a low-risk cohort, based on clinicopathologic features, who do not benefit from RT. A biosignature (DCISionRT^®) that evaluates recurrence risk has been developed and validated. We evaluated the impact of DCISionRT on clinicians’ recommendations for adjuvant RT.

Methods

The PREDICT study is a prospective, multi-institutional, observational registry in which patients underwent DCISionRT testing. The primary endpoint was to identify the percentage of patients where testing led to a change in RT recommendations.

Results

Overall, 539 women were included in this study. Pre DCISionRT testing, RT was recommended to 69% of patients; however, post-testing, a change in the RT recommendation was made for 42% of patients compared with the pre-testing recommendation; the percentage of women who were recommended RT decreased by 20%. For women initially recommended not to receive an RT pre-test, 35% had their recommendation changed to add RT following testing, while post-test, 46% of patients had their recommendation changed to omit RT after an initial recommendation for RT. When considered in conjunction with other clinicopathologic factors, the elevated DCISionRT score risk group (DS > 3) had the strongest association with an RT recommendation (odds ratio 43.4) compared with age, grade, size, margin status, and other factors.

Conclusions

DCISionRT provided information that significantly changed the recommendations to add or omit RT. Compared with traditional clinicopathologic features used to determine recommendations for or against RT, the factor most strongly associated with RT recommendations was the DCISionRT result, with other factors of importance being patient preference, tumor size, and grade.

     

Assessment of patient-independent intrinsic error for a noninvasive frame for fractionated stereotactic radiotherapy

The purpose of our study was to examine the extent of patient-independent intrinsic error associated with multiple, repeat remounting of the Laitinen Stereoadapter. The Laitinen frame was repeatedly mounted on a solid water phantom and imaged using computed tomography (CT). The phantom contained five targets located in the center, anterior, right, left, and posterior orientations. The images were processed, fused, and analyzed on the Pinnacle 3-D treatment planning system. The coordinate values (in the x, y, and z directions) for each target were determined for each mounting, and an absolute mean deviation was calculated for 11 repetitions. The mean deviation in the x, y, and z direction for the central and right target, and in the x and y direction for the posterior and anterior target was less than 2.0 mm. However, the mean error in the z direction of the anterior and posterior targets was 1.79 +/- 1.02 mm and 2.20 +/- 1.32 mm, respectively. Rotational misalignment during repeat frame fixation contributed to the observed deviations and in particular affected the antero-posterior plane. With the exception of two occasions where an obvious mounting error occurred, a significant portion of error from remounting the Laitinen Stereoadapter is associated with the operator and the imaging process. The observation of an angular displacement around the axis through the earplugs suggests that a certain degree of rotational misalignment in daily remounting is possible. Targets in the antero-posterior plane are most susceptible to localization error as a consequence of rotational misalignment. In summary, the overall error is within the limits of current imaging technology but not within submillimeter accuracy. Clinical application should take these errors into consideration when designing field margins.